Company Overview and News

73
Comstock Resources Eyes Enduro Resource Assets, Places Bid

2018-06-11 zacks
Comstock Resources, Inc. (CRK - Free Report) , according to recent reports, has placed its bid for the Cotton Valley and Haynesville Shale assets of bankrupt Enduro Resource Partners LLC, an exploration and production company that is liquidating its properties. Founded in 2010 and backed by the private equity firm, Riverstone Holdings, Enduro Resource was hit by low oil price environment that shook the industry a few years back.
WFC WFCNP APC WFC.WS CRK WFC.PRL WFC.PRJ REVSF WFC.PRT WFC.PRR WFC.PRQ DK WFC.PRP WFC.PRO WFC.PRN HFC WFC.PRY WFC.PRX AEUA WFC.PRW WFC.PRV AP4

11
Industry Leader Yields 11%, Major Growth Starting In Q2 2018, Industry Turnaround

2018-05-17 seekingalpha
It reported record Q1 '18 earnings and closed on a major deal at the start of Q2 '18.
ETP.PRC ETP USAC REVSF AP4

4
OTC2018: CEO of 'Reset' Deepwater Operator Sees Better Days for GOM

2018-05-04 rigzone
The overall increase in crude oil prices notwithstanding, a “new attitude” toward U.S. Gulf of Mexico (GOM) operators among federal government regulators and the White House is helping deepwater oil and gas firms to better position themselves for growth in the short and long terms, the head of one of the largest GOM operators told Rigzone.
NBL REVSF AP4

4
CEO of 'Reset' Deepwater Operator Sees Better Days for Gulf of Mexico

2018-05-04 rigzone
The overall increase in crude oil prices notwithstanding, a “new attitude” toward U.S. Gulf of Mexico (GOM) operators among federal government regulators and the White House is helping deepwater oil and gas firms to better position themselves for growth in the short and long terms, the head of one of the largest GOM operators told Rigzone.
NBL REVSF AP4

4
Brian Alfaro Discusses the Strong M&A Interest in Permian Basin

2018-05-02 accesswire
SAN ANTONIO, TX / ACCESSWIRE / May 2, 2018 / Oil and gas (O&G) industry merger and acquisition (M&A) activities slowed for most of 2017, largely due to drillers focusing on consolidating their positions in a few core areas to contend with low oil prices by purchasing assets that allowed to connect pieces of land, drill more efficiently and improve cash flow. However, the money is starting to return this year with large energy companies playing a major role in deal making.
REVSF AP4

39
The AES Corporation - Potential 'Power' King?

2018-04-18 seekingalpha
Since 2012, AES has been under new management, expanded in countries where it could make a potential profit and exited the high-risk ones.
AES.PRC WM AES REVSF AP4

59
Blackstone Fund Buys Stake in Property Firm Rockpoint - Bloomberg

2018-03-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
JBK GSC GS.PRICL TFG GS.PRB GS.PRA GSJ REVSF GS.PRJ GS.PRI GS GLSSP GS.PRD GS.PRC GJS GS.PRN GS.PRK AP4

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

13h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

13h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...